|
2024 Journal Article Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyMcLean, Luke S, Lim, Annette M, Bressel, Mathias, Lee, Jenny, Ladwa, Rahul, Guminski, Alexander D, Hughes, Brett, Bowyer, Samantha, Briscoe, Karen, Harris, Samuel, Kukard, Craig, Zielinski, Rob, Alamgeer, Muhammad, Carlino, Matteo, Mo, Jeremy, Park, John J, Khattak, Muhammad A, Day, Fiona and Rischin, Danny (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220 (2), 80-90. doi: 10.5694/mja2.52199 |
|
2024 Journal Article Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapyBlake, Claire, Lai, Rainbow, Brown, Teresa, Pelecanos, Anita, Moroney, Laura, Helios, Jennifer, Smith, David, Hughes, Brett G. M., Kenny, Lizbeth, Chua, Benjamin and Bauer, Judith (2024). Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy. Journal of Human Nutrition and Dietetics, 37 (1), 182-192. doi: 10.1111/jhn.13243 |
|
2023 Journal Article Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2023). Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629. Dermatology and Therapy, 13 (12), 3165-3180. doi: 10.1007/s13555-023-01059-y |
|
2023 Journal Article A tailored approach to horizon scanning for cancer medicinesSoon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J. ... IJzerman, Maarten (2023). A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy, 38 100441, 1-8. doi: 10.1016/j.jcpo.2023.100441 |
|
2023 Journal Article Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyGross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo Bernard, Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G. M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Yoo, Suk-Young, Mathias, Melissa, Han, Hyunsil, Seebach, Frank, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2023). Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet Oncology, 24 (11), 1196-1205. doi: 10.1016/S1470-2045(23)00459-X |
|
2023 Journal Article Development and validation of txSim: A model of advanced lung cancer treatment in AustraliaNgo, Preston, Karikios, Deme, Goldsbury, David, Wade, Stephen, Lwin, Zarnie, Hughes, Brett G. M., Fong, Kwun M., Canfell, Karen and Weber, Marianne (2023). Development and validation of txSim: A model of advanced lung cancer treatment in Australia. PharmacoEconomics, 41 (11), 1525-1537. doi: 10.1007/s40273-023-01291-6 |
|
2023 Journal Article Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironmentJhaveri, Niyati, Ben Cheikh, Bassem, Nikulina, Nadezhda, Ma, Ning, Klymyshyn, Dmytro, DeRosa, James, Mihani, Ritu, Pratapa, Aditya, Kassim, Yasmin, Bommakanti, Sidharth, Shang, Olive, Berry, Shannon, Ihley, Nicholas, McLane, Michael, He, Yan, Zheng, Yi, Monkman, James, Cooper, Caroline, O'Byrne, Ken, Anand, Bhaskar, Prater, Michael, Basu, Subham, Hughes, Brett G. M., Kulasinghe, Arutha and Braubach, Oliver (2023). Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment. GEN Biotechnology, 2 (5), 418-434. doi: 10.1089/genbio.2023.0029 |
|
2023 Journal Article Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapySadeghirad, Habib, Liu, Ning, Monkman, James, Ma, Ning, Cheikh, Bassem Ben, Jhaveri, Niyati, Tan, Chin Wee, Warkiani, Majid Ebrahimi, Adams, Mark N., Nguyen, Quan, Ladwa, Rahul, Braubach, Oliver, O’Byrne, Ken, Davis, Melissa, Hughes, Brett G. M. and Kulasinghe, Arutha (2023). Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy. Frontiers in Immunology, 14 1135489, 1-16. doi: 10.3389/fimmu.2023.1135489 |
|
2023 Journal Article LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancerAlexander, Marliese, Wei, Joe, Parakh, Sagun, John, Thomas, Kao, Steven, Nagrial, Adnan, Bowyer, Samantha, Warburton, Lydia, Moore, Melissa, Hughes, Brett G. M., Clay, Timothy D., Pavlakis, Nick, Solomon, Benjamin J. and Itchins, Malinda (2023). LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer. JTO Clinical and Research Reports, 4 (4) 100490, 1-13. doi: 10.1016/j.jtocrr.2023.100490 |
|
2023 Journal Article Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapyBlake, Claire L., Brown, Teresa E., Pelecanos, Anita, Moroney, Laura B., Helios, Jennifer, Hughes, Brett G. M., Chua, Benjamin and Kenny, Lizbeth M. (2023). Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy. Head and Neck, 45 (2), 417-430. doi: 10.1002/hed.27249 |
|
2023 Journal Article Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/dayTaylor, Matthew H., Leboulleux, Sophie, Panaseykin, Yury, Konda, Bhavana, de La Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Park, Young Joo, Romanov, Ilia, Krzyzanowska, Monika K., Garbinsky, Diana, Sherif, Bintu, Pan, Jie Janice, Binder, Terri A., Sauter, Nicholas, Xie, Ran and Brose, Marcia S. (2023). Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine, 12 (4), 4332-4342. doi: 10.1002/cam4.5308 |
|
2022 Journal Article Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancerMiller, Richard A., Luke, Jason John, Hu, Shenshen, Mahabhashyam, Suresh, Jones, William B., Marron, Thomas, Merchan, Jaime R., Hughes, Brett G. M. and Willingham, Stephen B. (2022). Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for ImmunoTherapy of Cancer, 10 (12) e005802, e005802. doi: 10.1136/jitc-2022-005802 |
|
2022 Journal Article Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort studyJiang, Yingying, Shi, Yue, Liu, Yiling, Wang, Zihan, Ma, Yuxin, Shi, Xinhong, Lu, Lin, Wang, Zhitong, Li, Hang, Zhang, Yushu, Liu, Caolu, Zhang, Shaorui, Zhong, Zhihao, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Yin, Rong, Galetta, Domenico, Grenda, Anna, Romero, Atocha, Hughes, Brett G. M., Chen, Cheng, Wang, Xiaohua and Feng, Jifeng (2022). Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. Translational Lung Cancer Research, 11 (12), 2521-2538. doi: 10.21037/tlcr-22-857 |
|
2022 Journal Article Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 StudyHarrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F. and Rischin, Danny (2022). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41 (4), 790-802. doi: 10.1200/jco.21.02508 |
|
2022 Journal Article Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinomaGross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G. and Rischin, Danny (2022). Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. New England Journal of Medicine, 387 (17), 1557-1568. doi: 10.1056/nejmoa2209813 |
|
2022 Journal Article Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic reviewEdwards, Anna, Hughes, Brett G M, Brown, Teresa and Bauer, Judith (2022). Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review. Advances in Nutrition, 13 (6), 2433-2444. doi: 10.1093/advances/nmac076 |
|
2022 Journal Article Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive scoreBurtness, Barbara, Rischin, Danny, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Ge, Joy, Swaby, Ramona F., Gumuscu, Burak and Harrington, Kevin (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. Journal of Clinical Oncology, 40 (21), 2321-2332. doi: 10.1200/jco.21.02198 |
|
2022 Journal Article Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancerKapeleris, Joanna, Bark, Juliana Müller, Ranjit, Shanon, Irwin, Darryl, Hartel, Gunter, Warkiani, Majid Ebrahimi, Leo, Paul, O’Leary, Connor, Ladwa, Rahul, O'Byrne, Kenneth, Hughes, Brett G.M. and Punyadeera, Chamindie (2022). Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 8 (7) e09971, 1-9. doi: 10.1016/j.heliyon.2022.e09971 |
|
2022 Journal Article Application of circulating tumour cells to predict response to treatment in head and neck cancerZhang, Xi, Ekanayake Weeramange, Chameera, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid Ebrahimi, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz and Punyadeera, Chamindie (2022). Application of circulating tumour cells to predict response to treatment in head and neck cancer. Cellular Oncology, 45 (4), 1-13. doi: 10.1007/s13402-022-00681-w |
|
2022 Journal Article A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancerCapdevila, Jaume, Klochikhin, Arkadiy, Leboulleux, Sophie, Isaev, Pavel, Badiu, Corin, Robinson, Bruce, Hughes, Brett G.M., Keam, Bhumsuk, Parnis, Francis, Elisei, Rossella, Gajate, Pablo, Gan, Hui K., Kapiteijn, Ellen, Locati, Laura, Mangeshkar, Milan, Faoro, Leonardo, Krajewska, Jolanta and Jarzab, Barbara (2022). A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer. Thyroid, 32 (5), 515-524. doi: 10.1089/thy.2022.0027 |
